Immuno-Oncology | Specialty

Key Takeaway 5: Dosing of Multiple Kinase Inhibitors

September 16th 2019

Key Takeaway 4: Right-Sided Tumors: Anti-Angiogenic Treatment

September 16th 2019

Key Takeaway 3: Determining Tumor Mutational Status

September 16th 2019

Key Takeaway 2: Frontline Neoadjuvant Chemotherapy

September 16th 2019

Key Takeaway 1: Adjuvant Therapy Optimal Duration

September 16th 2019

Novel Lung Cancer Therapy: Future Improvements and Challenges

September 6th 2019

MET as a Clinical Target in Lung Cancer

September 6th 2019

Expanding the NSCLC Armamentarium: IMpower131

September 6th 2019

Extensive-Stage SCLC: Potential in the CASPIAN Trial

September 6th 2019

Targeted Therapy for KRAS p.G12C NSCLC

September 6th 2019

Future Directions in Lung Cancer Management

September 6th 2019

Metastatic NSCLC: Interpreting Data From NEPTUNE

September 6th 2019

Updated Data in Stage IV NSCLC: CheckMate-227

September 6th 2019

LIBRETTO-001: Targeting RET Fusions in Advanced-Stage NSCLC

September 6th 2019

Advanced-Stage NSCLC: Overall Survival Data From FLAURA

September 6th 2019

Overview of Novel Therapy for Advanced-Stage NSCLC

September 6th 2019

Key Takeaway 6: Role of Immunotherapy in R/R mHCC

August 15th 2019

Key Takeaway 5: High AFP is a Biomarker for Ramucirumab

August 15th 2019

Key Takeaway 4: Second-Line Regorafenib After TKI in HCC

August 15th 2019

Key Takeaway 3: Role of Frontline I/O Still Pending

August 15th 2019